Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.57 |
| ▸ | EGFR | P00533 | 7/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.51 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5651340 | 0.96 | KDR (0.59) | KDREGFRFGFR1FLT1ERBB2 | |
| SCHEMBL5652274 | 0.93 | KDR (0.63) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5650425 | 0.93 | KDR (0.59) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5650863 | 0.91 | KDR (0.60) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5652828 | 0.90 | KDR (0.60) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5651546 | 0.90 | KDR (0.59) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5650422 | 0.89 | KDR (0.54) | KDREGFRFGFR1FLT1ERBB2 | |
| SCHEMBL5651894 | 0.89 | KDR (0.59) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5651977 | 0.88 | KDR (0.66) | KDREGFRFGFR1FLT1FBP1 | |
| SCHEMBL5652242 | 0.88 | KDR (0.69) | KDREGFRFGFR1FLT1FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | KDR 1/4885EGFR 439/4885FGFR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.